Etonogestrel implant in women with diabetes mellitus

References

• World Health Organization. The medical eligibility criteria for contraceptive use3rd ed. 2004, Accessed at http://www.who.int/topics/reproductive_health/en/
   Google Scholar
• ACOG Practice Bulletin N.73 Use of hormonal contraception in women with coexisting medical conditions. Obstet Gynecol 2006; 107: 1453–1472
   PubMedGoogle Scholar
• UK Medical eligibility criteria for contraceptive use. 2005/2006, Accessed at www.fffprhc.org.uk
   Google Scholar
• Schwarz E B, Maselli J, Gonzales R. Contraceptive counseling of diabetic women of reproductive age. Obstet Gynecol 2006; 107: 1070–1074
   PubMed Web of Science ®Google Scholar
• Napoli A, Colatrella A, Botta R, et al. Contraception in diabetic women: An Italian study. Diabetes Res Clin Pract 2005; 67: 267–272
   PubMed Web of Science ®Google Scholar
• Kimmerle R, Schmitt G, Berger M. Empfängnisverhütung bei Typ-I-Diabetikerinnen: Eine Erhebung bei 808 Frauen in fertilen Alter. (Contraception in patients with type 1 diabetes: A survey of 808 women of reproductive age). Geburtshilfe Frauenheilkd 1994; 54: 691–696
   PubMedGoogle Scholar
• Visser J, Snel M, Van Vliet H AAM, Hormonal versus non-hormonal contraceptives in women with diabetes mellitus type 1 and 2. Cochrane Database of Systematic Reviews 2006, issue 4. Art. No:CD003990. DOI:10.1002/14651858.CD003990.pub3
   Google Scholar
• Godsland I F, Crook D. Update on the metabolic effects of steroidal contraceptives and their relationship to cardiovascular disease risk. Am J Obstet Gynecol 1994; 170: 1528–1536
   PubMed Web of Science ®Google Scholar
• Godsland I F. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med 1990; 323: 1375–1381
   PubMed Web of Science ®Google Scholar
• Godsland I F, Walten C, Felten C, et al. Insulin resistance, secretion and metabolism in users of oral contraceptives. J Clin Endocrinol Metab 1992; 74: 64–70
   PubMed Web of Science ®Google Scholar
• Petersen K R. Pharmacodynamic effects of oral contraceptive steroids on biochemical markers for arterial thrombosis. Studies in non-diabetic women and in women with insulin-dependent diabetes mellitus. Dan Med Bull 2002; 49: 43–60
   PubMed Web of Science ®Google Scholar
• Crook D, Godsland I F, Worthing M, et al. A comparative metabolic study of two low-estrogen-dose oral contraceptives containing desogestrel or gestodene progestins. Am J Obstet Gynecol 1993; 169: 1183–1189
   PubMed Web of Science ®Google Scholar
• Dorflinger L J. Metabolic effects of implantable steroid contraceptives for women. Contraception 2002; 65: 47–62
   PubMed Web of Science ®Google Scholar
• Edwards J E, Moore A. Implanon. A review of clinical studies. Br J Fam Plann 1999; 24(Suppl. 4)3–16
   PubMedGoogle Scholar
• Biswas A, Viegas O AC, Bennink H JTC, et al. Implanon contraceptive implants: Effects on cardohydrate metabolism. Contraception 2001; 63: 137–141
   PubMed Web of Science ®Google Scholar
• Biswas A, Viegas O AC, Roy A C. Effect of Implanon and Norplant subdermal contraceptive implants on serum lipids. A randomized comparative study. Contraception 2003; 68: 189–193
   PubMed Web of Science ®Google Scholar
• Suherman S K, Affandi B, Korver T. The effect of Implanon on lipid metabolism in comparison with Norplant. Contraception 1999; 60: 281–287
   PubMed Web of Science ®Google Scholar
• Mascarenhas L, van Beek A, Bennink H C, Newton J. Twenty-four months comparison of apolipoproteins AI, AII and B in contraceptive implant users (Norplant and Implanon) in Birmingham, United Kingdom. Contraception 1998; 58: 215–219
   PubMed Web of Science ®Google Scholar
• Hickey A, d'Arcangues C. Vaginal bleeding disturbances and implantable contraceptives. Contraception 2002; 65: 75–84
   PubMed Web of Science ®Google Scholar
• Kiriwat O, Patanayindee A, Koetsawang S, et al. A 4-year pilot study on the efficacy and safety of Implanon, a single-rod hormonal contraceptive implant, in healthy women in Thailand. Eur J Contracept Reprod Health Care 1998; 3: 85–91
   PubMedGoogle Scholar
• Mansour D, Korver T, Petrova-Marintcheva M, Fraser I S. The effects of Implanon on menstrual bleeding patterns. Eur J Contracept Reprod Health Care 2008; 13(Suppl. 1)13–18
   PubMed Web of Science ®Google Scholar
• Sergent F, Clamageran C, Bastard A M, et al. Acceptabilité de l'implant contraceptif à l'étonogestrel (Acceptability of the contraceptive etonogestrel implant.). J Gynecol Obstet Biol Reprod 2004; 33: 407–415
   PubMedGoogle Scholar
• Belsey E M, Farley T MM. The analysis of menstrual bleeding patterns. A review. Contraception 1988; 38: 129–156
   PubMed Web of Science ®Google Scholar
• Buse J B, Ginsberg H N, Bakris G L, et al. Primary prevention of cardiovascular diseases in people with diabetes mellitus: A scientific statement from the American Heart Association and the American Diabetic Association. Diabetes Care 2007; 30: 162–172
   PubMed Web of Science ®Google Scholar
• Hohmann H, Creinin M. The contraceptive implant. Clin Obstet Gynecol 2007; 50: 907–917
   PubMed Web of Science ®Google Scholar
• Brache V, Faundes A, Alvarez F, Cochon L. Non-menstrual adverse events during use of implantable contraceptives for women: Data from clinical trials. Contraception 2002; 65: 63–74
   PubMed Web of Science ®Google Scholar
• Urbancsek J. An integrated analysis of nonmenstrual adverse events with Implanon. Contraception 1998; 58: 109S–115S
   PubMed Web of Science ®Google Scholar
• Funk S, Miller M M, Mishell D R, et al. A multicentre efficacy and safety study of the contraceptive implant containing etonogestrel. Contraception 2005; 71: 319–326
   PubMed Web of Science ®Google Scholar
• Glasier A F, Smith K B, Spudy Z M, et al. Amenorrhea associated with contraception – An international study on acceptability. Contraception 2003; 67: 1–8
   PubMed Web of Science ®Google Scholar
• Meirik O, Fraser I S, D'Arcangues C. Implantable contraceptives for women. Hum Reprod Update 2003; 9: 49–59
   PubMed Web of Science ®Google Scholar